Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
Vincenzo M MondaClaudio VociFelice StrolloAngelina PassaroSalvatore GrecoMarcello MonesiRenato BigoniFrancesca PorcellatiDaniela PianiErsilia SattaSandro GentilePublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
The aforedescribed observational clinical data relating to a population of Italian inpatients with T2DM suggest that GLP-1ras and SGLT-2is can be considered antidiabetic drugs of choice against COVID-19, and might even prove beneficial in the event of any upcoming pandemic that has life-threatening effects on the pulmonary and cardiovascular systems.
Keyphrases
- coronavirus disease
- intensive care unit
- sars cov
- emergency department
- pulmonary hypertension
- healthcare
- cardiovascular events
- electronic health record
- respiratory syndrome coronavirus
- mechanical ventilation
- risk factors
- cardiovascular disease
- metabolic syndrome
- adipose tissue
- wild type
- decision making
- extracorporeal membrane oxygenation
- smoking cessation